Table 1. Patients’ characteristics (n=38).
Variables | Median (range)/frequency (%) |
---|---|
Age [years] | 58.6 [40-75] |
Sex | |
Male | 15 (39.5) |
Female | 23 (60.5) |
Smoking status | |
Smoker | 11 (28.9) |
Never-smoker | 27 (71.1) |
Performance status | |
0-1 | 32 (84.2) |
2 | 6 (15.8) |
First-line chemotherapy | |
Pemetrexed plus cisplatin | 22 (57.9) |
Pemetrexed plus carboplatin | 10 (26.3) |
Pemetrexed single use | 6 (15.8) |
Icotinib treatment | |
Second line | 27 (71.1) |
Maintenance | 11 (28.9) |
Post-study treatment | |
Paclitaxel | 12 (31.5) |
Platinum | 10 (26.3) |
Docetaxel | 9 (23.6) |
Gemcitabine | 8 (21.0) |
None | 6 (15.7) |
Other EGFR-TKIs | 6 (15.7) |
EGFR-TKIs, epidermal growth factor receptor tyrosine kinase inhibitors.